Recently, A-Shares fluctuated widely, and the pharmaceutical sector was also impacted, but it showed obvious resistance to decline, and several stocks had a strong trend.
According to statistics, the reporter found that last week (March 7-11), all 31 Shenwan pharmaceutical and biological industries fell, and the Shenwan pharmaceutical and biological industry index fell 2.07%, lower than most industries. Among the top ten stocks with weekly gains in a shares, pharmaceutical stocks accounted for four seats, Changjiangrunfa Health Industry Co.Ltd(002435) , Ningbo Menovo Pharmaceutical Co.Ltd(603538) , China Meheco Group Co.Ltd(600056) , Peking University Hospital, with weekly gains of 61.11%, 46.55%, 41.71% and 34.78% respectively.
Stimulated by the news of “holding Pfizer in hand”, China Meheco Group Co.Ltd(600056) rose for five consecutive trading days last week, including three-day limit. The company announced on the 11th that it signed an agreement with Pfizer on March 9, 2022 and issued Lin 2022007 announcement on signing an agreement with Pfizer on March 10. The company will be responsible for the commercial operation of Pfizer Inc COVID-19 virus PAXLOVID in Chinese mainland market during the agreement period (2022). On February 11, 2022, the State Drug Administration approved the import registration of the product with conditions. This product is a prescription drug, which has not yet entered the national medical insurance and covid-19 pneumonia diagnosis and treatment plan. The final use and sales are affected by epidemic prevention and control and other factors, and it is expected that the relevant business scale accounts for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent business performance.
API enterprise Ningbo Menovo Pharmaceutical Co.Ltd(603538) walked out of the fourth board. The company responded to market rumors in the announcement of stock price changes on the 11th. The announcement shows that the company is promoting the international MPP (Geneva pharmaceutical patent pool organization) authorization application, but it has not obtained the relevant authorization as of the submission date of this announcement, and there is still great uncertainty about whether it can obtain the authorization in the future. In addition, in view of the investors’ concern about whether the company has arranged the auxiliary reproduction and pension business industry, Ningbo Menovo Pharmaceutical Co.Ltd(603538) disclosed that the company’s main business does not involve the auxiliary reproduction and pension industry. The company’s 32% equity participation of Ruihe fund invested 7.5% equity of MEC medicine. Ruihe fund and mec medicine are not within the scope of the company’s consolidated statements, and the proportion of equity participation is small.
At the performance level, a number of pharmaceutical companies recently disclosed monthly operating data, releasing good performance. Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) announced that according to the company’s preliminary accounting, from January to February 2022, the company achieved a total operating revenue of about 1.6 billion yuan, an increase of about 16% year-on-year; The net profit attributable to the shareholders of the listed company was about 600 million yuan, a year-on-year increase of about 20%. Among CXO (pharmaceutical service outsourcing) stocks, Wuxi Apptec Co.Ltd(603259) announced that from January to February 2022, the year-on-year growth rate of orders in hand and sales revenue exceeded 65%, a record high. The company expects the year-on-year growth of revenue in the first quarter of 2022 to reach 65% to 68% Hangzhou Tigermed Consulting Co.Ltd(300347) announced that according to the preliminary accounting of the company, the newly signed orders increased by more than 65% year-on-year from January to February 2022, and the operating revenue increased by more than 100% year-on-year.
At the policy level, institutions generally pay attention to the guidance and outlook of the government work report on the medical and health work and the pharmaceutical industry in 2022 Du Xiangyang, chief analyst of Southwest Securities Co.Ltd(600369) pharmaceutical industry, believes that this year’s government work report once again shows the government’s support for pharmaceutical innovation and improving the medical service system, as well as its concern to expand the coverage of medical insurance and improve the efficiency of the use of medical insurance funds. Through volume procurement, medical insurance cost control has achieved initial results. It is expected to continue to implement the volume procurement policy without affecting the innovation of enterprises, expand the coverage, enrich the medical insurance fund, improve the quality of medical services, improve the medical service system, and form the “three medical” linkage Zheshang Securities Co.Ltd(601878) analyst Sun Jian said that the government work report showed that China continued to strengthen its efforts on the route of “ensuring basic and wide coverage” of medical insurance; Accelerate the reform of public hospitals; Strengthening the independent control of the industrial chain and “grasping manufacturing and welcoming innovation” remain the main investment line of the pharmaceutical sector in 2022. “We suggest that investors break the ‘core assets’ and’ sector concept ‘so that they can look at the investment opportunities in the upstream and manufacturing links with the thinking of industrial chain.”
